



Unbiased screening identifies functional differences in NK cells after early life psycho-sociological stress

Sara B. Fernandes^{1,2}, Neha D. Patil^{1,2}, Sophie Meriaux¹, Maud Theresine¹, Claude. P. Muller¹, Fleur A.D. Leenen^{1,3}, Martha M.C. Elwenspoek^{1,4}, Jacques Zimmer^{1,2}, Jonathan Turner¹ *

Supplementary figure 1: viSNE clusters definition based on the used markers. Clusters colored by CD3, CD4 and CD8 cell markers to identify immune populations associated. Blue to orange: low to high expression of the marker.




Supplementary figure 1: viSNE clusters definition based on the used markers. Clusters colored by CD3, CD4 and CD8 cell markers to identify immune populations associated. Blue to orange: low to high expression of the marker.




Supplementary figure 2: Clusters colored by CD45RA, CD11b/c, CD25 and FoxP3 cell markers to identify immune populations associated. Blue to orange: low to high expression of the marker.




Supplementary figure 2: Clusters colored by CD45RA, CD11b/c, CD25 and FoxP3 cell markers to identify immune populations associated. Blue to orange: low to high expression of the marker.









Supplementary figure 2: Clusters colored by CD45RA, CD11b/c, CD25 and FoxP3 cell markers to identify immune populations associated. Blue to orange: low to high expression of the marker.







Supplementary figure 3: FlowJo gating strategy for the quantification of NK and NKT-like cells



Supplementary figure 4: FlowJo gating strategy for the quantification of NK cell maturation state.



Supplementary figure 5: Correlation analysis between CMV titers and cytotoxic response of NK cells of institutionalized individuals. .



Supplementary figure 6: (A): representative image of the NK cell population gating strategy: 1- CD56^{bright}CD16⁻; 2 -CD56^{bright}CD16⁺; 3- CD56^{dim}CD16⁺; 4- CD56^{dim}CD16^{dim}; 5- CD56^{dim}CD16^{bright}; 6 - CD56⁻CD16^{bright}. Rest of the figures show the release of IFN- γ and CD107a by the different NK cell populations. No significant differences were found. Data is presented as mean \pm SEM of 14 donor per group.











Table 1 – Description of the antibodies used for immunophenotyping.

| IMMUNOPHENOTYPING | | | |
|------------------------------------|--------------------|--------------|--------------------------------|
| Cell type | Antibody | Laser | Reference |
| T cells | CD3 | FITC | BD 559975 |
| T helper cell | CD4 | BV510 | BD 740138 |
| T cytotoxic cell | CD8 | BUV395 | BD 740257 |
| B cells | CD45RA | PE Cy5 | BD 561624 |
| Activation marker | CD25 | BV650 | BD 742755 |
| NK cells | CD161a | BV605 | BD 744051 |
| Macrophages, dendritic cells | CD11b/c | BB700 | BD 746165 |
| Activation marker B cells | RT1B | BV786 | BD 744131 |
| T regulatory cells | FoxP3 | APC | BD 566527 |
| Viability marker | Live/Dead | APC Cy7 | Biologend 423105 |
| NK CELL MATURATION ASSAY | | | |
| T cells | CD3 | PerCP Cy5.5 | ThermoFisher 46-0030-82 |
| NK cell | CD161a | BV605 | BD BV605 |
| NK cell phenotypic marker | NKp46 (CD335) | APC | Biologend, 250808 |
| NK cells maturation marker | CD27 | BUV737 | BD 612831 |
| NK cells maturation marker | CD11b | PE | BD 562105 |
| Viability marker | Live/Dead | APC-Cy7 | Biologend 423105 |
| NK CELL CYTOTOXICITY ASSAY | | | |
| Viability marker | TO-PRO | APC | ThermoFisher Scientific T3605 |
| Viability marker | Cell Tracer Violet | Pacific Blue | ThermoFisher Scientific C34571 |
| NK CELL DEGRANULATION ASSAY | | | |
| T cells | CD3 | BV510 | BD 563109 |
| NK cell phenotypic marker | CD19 | PE-Cy5 | Biologend 302210 |
| NK cell phenotypic marker | CD16 | BUV496 | BD 564653 |
| NK cell phenotypic marker | CD56 | BV711 | BD 563169 |
| NK cell functional marker | CD107a | FITC | Biologend 328606 |
| Cytokine | IFN γ | PE | BD 502509 |
| Viability marker | Cell Tracer Violet | Pacific Blue | ThermoFisher Scientific C34571 |
| Viability marker | Live/Dead | APC Cy7 | Biologend 423105 |

Table 2 - Clusters obtained from viSNE unbiased phenotyping. Association of the markers used with each cluster and p values obtained after statistical analysis.

| Cluster | Markers | CTR vs MD ₁₅ | CTR vs MD ₁₈₀ | MD ₁₅ vs MD ₁₈₀ |
|---------|--|-------------------------|--------------------------|---------------------------------------|
| 1 | CD3 ⁺ ; CD4 ⁺ ; CD25 ⁺ ; FoxP3 ⁺ | 3.73E-10 | 1.86E-08 | 3.29E-01 |
| 2 | CD3 ⁺ ; CD4 ⁺ | 5.39E-05 | 2.55E-01 | 5.10E-03 |
| 3 | CD3 ⁺ ; CD4 ⁺ | 5.30E-03 | 9.31E-01 | 1.34E-02 |
| 4 | CD3 ⁺ ; CD4 ⁺ | 4.91E-03 | 2.82E-03 | 9.77E-01 |
| 5 | CD3 ⁺ ; CD4 ⁺ | 6.70E-01 | 7.41E-02 | 9.92E-03 |
| 6 | CD45RA ⁺ ; RT1B ⁺ | 3.44E-03 | 4.86E-02 | 5.40E-01 |
| 7 | CD45RA ⁺ ; RT1B ⁺ | 4.13E-01 | 1.25E-02 | 3.82E-04 |
| 8 | CD3 ⁺ ; CD8 ⁺ | 7.56E-01 | 1.65E-03 | 1.10E-02 |
| 9 | CD3 ⁺ ; CD4 ⁺ | 2.62E-14 | 1.73E-13 | 6.59E-01 |
| 10 | CD3 ⁺ ; CD4 ⁺ | 9.93E-01 | 2.18E-03 | 3.00E-03 |
| 11 | CD3 ⁺ ; CD4 ⁺ | 7.33E-07 | 1.27E-05 | 5.99E-01 |
| 12 | CD3 ⁺ ; CD4 ⁺ | ns | ns | ns |
| 13 | CD45RA ⁺ | 7.18E-05 | 3.01E-01 | 5.00E-03 |
| 14 | CD45RA ⁺ ; RT1B ⁺ | 3.05E-05 | 7.55E-01 | 2.47E-04 |
| 15 | CD3 ⁺ ; CD8 ⁺ | ns | ns | ns |
| 16 | CD3 ⁺ ; CD8 ⁺ | 3.31E-02 | 7.98E-02 | 9.16E-01 |
| 17 | RORγT ⁺ | ns | ns | ns |
| 18 | CD11b/c ⁺ | 1.70E-06 | 5.57E-09 | 1.25E-01 |
| 19 | CD11b/c ⁺ | 1.73E-07 | 6.70E-05 | 1.19E-01 |
| 20 | CD11b/c ⁺ | 9.10E-01 | 3.13E-02 | 1.15E-02 |
| 21 | CD45RA ⁺ ; RT1B ⁺ | 4.42E-06 | 1.55E-07 | 4.90E-01 |
| 22 | CD3 ⁺ ; CD8 ⁺ | 8.44E-04 | 1.52E-01 | 9.81E-02 |
| 23 | CD8 ⁺ ; | 1.89E-02 | 1.23E-01 | 6.75E-01 |
| 24 | CD11b/c ⁺ | ns | ns | ns |
| 25 | CD11b/c ⁺ | 4.30E-03 | 3.79E-01 | 1.05E-01 |
| 26 | CD11b/c ⁺ | 2.45E-03 | 4.49E-04 | 8.18E-01 |
| 27 | CD45RA ⁺ ; RT1B ⁺ | 1.33E-12 | 2.01E-06 | 1.79E-05 |
| 28 | CD45RA ⁺ ; RT1B ⁺ | 1.28E-06 | 2.85E-06 | 9.60E-01 |
| 29 | CD161a ⁺ | 6.92E-01 | 9.65E-03 | 6.71E-02 |
| 30 | CD8 ⁺ ; CD11b/c ⁺ | 1.40E-01 | 3.12E-02 | 7.61E-01 |
| 31 | CD11b/c ⁺ | ns | ns | ns |
| 32 | CD11b/c ⁺ | 8.62E-13 | 3.12E-07 | 6.76E-05 |
| 33 | CD11b/c ⁺ | 4.58E-10 | 8.47E-04 | 4.29E-05 |
| 34 | CD45RA ⁺ ; RT1B ⁺ | 1.87E-02 | 4.19E-04 | 3.44E-01 |
| 35 | CD45RA ⁺ ; RT1B ⁺ | 4.30E-14 | 4.45E-09 | 1.06E-04 |
| 36 | CD8 ⁺ ; CD161a ⁺ ; Tbet ⁺ | 5.63E-05 | 1.14E-05 | 8.51E-01 |
| 37 | CD8 ⁺ ; CD161a ⁺ | 2.08E-03 | 4.46E-07 | 1.70E-02 |
| 38 | CD11b/c ⁺ | 5.88E-07 | 1.68E-05 | 4.94E-01 |
| 39 | CD11b/c ⁺ | 2.45E-01 | 6.00E-03 | 2.24E-01 |
| 40 | CD11b/c ⁺ | ns | ns | ns |
| 41 | CD45RA ⁺ ; RT1B ⁺ | 1.43E-02 | 9.37E-01 | 3.25E-02 |
| 42 | CD45RA ⁺ ; RT1B ⁺ | 1.64E-01 | 6.57E-01 | 2.55E-02 |
| 43 | CD8 ⁺ ; CD161a ⁺ ; Tbet ⁺ | 5.87E-07 | 3.89E-03 | 1.21E-02 |
| 44 | CD8 ⁺ ; CD161a ⁺ ; Tbet ⁺ | 4.94E-01 | 1.23E-02 | 1.54E-01 |
| 45 | CD11b/c ⁺ | ns | ns | ns |
| 46 | CD11b/c ⁺ | 3.28E-07 | 2.49E-05 | 3.14E-01 |
| 47 | CD161a ⁺ | 6.67E-08 | 3.21E-07 | 8.48E-01 |
| 48 | CD45RA ⁺ ; RT1B ⁺ | 2.61E-04 | 1.82E-01 | 3.23E-02 |
| 49 | CD45RA ⁺ ; RT1B ⁺ | 2.94E-01 | 4.86E-03 | 1.60E-01 |